rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TVTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Travere at Jefferies Global Healthcare Conference: growth, pipeline and runway
      Nov 17Investing.comTVTX
      Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling Buy (TVTX)
      Nov 16Seeking AlphaTVTX
      Travere Therapeutics at UBS conference: filspari drives growth
      Nov 16Investing.comTVTX
      Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 12Yahoo FinanceTVTX
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Inspire Medical Systems (INSP) and Travere Therapeutics (TVTX)

      Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

      Nov 4The Globe and MailJAZZTVTXINSP
      Travere Therapeutics to Participate at Upcoming Investor Conferences
      Nov 3Yahoo FinanceTVTX
      Ex-Biotech Darling Is On A Crash Course With Its 200-Day Line

      Shares of Travere Therapeutics took a hit Tuesday after fewer than expected patients started treatment with its kidney drug.

      Nov 3Investor's Business DailyTVTX
      Why is Travere Therapeutics stock sliding today?
      Nov 3Investing.comTVTX
      Travere Therapeutics, Inc. Q3 2026 Earnings Call Summary
      Nov 3Yahoo FinanceTVTX
      Why Travere Therapeutics (TVTX) Could Be 34% Undervalued On Its Q3 Loss

      Q3 earnings swing to loss as revenue rises Travere Therapeutics (TVTX) just delivered third quarter 2026 numbers that pulled investor attention to both sides of the income statement. Revenue reached US$224.56 million while the company moved from profit to a net loss. The biopharma group focused on rare kidney and metabolic diseases reported a net loss of US$52.34 million for the quarter. In the same period a year earlier it had posted net income of US$25.71 million. On a per share basis,...

      Nov 3Yahoo FinanceTVTX
      Travere Therapeutics (TVTX) Stock Looks Fully Priced After Its 7x Run

      Travere Therapeutics has delivered a very large 3 year share price gain, which naturally puts the spotlight on whether the current valuation can be explained by its sales base. With the stock around US$49.26 after some recent pullback, the question is how that share price lines up with what the business is generating from its commercial portfolio. Travere Therapeutics has returned roughly 7x over the past 3 years, which puts a lot of weight on whether revenue today and potential future sales...

      Nov 3Yahoo FinanceTVTX
      What Could Travere Therapeutics (TVTX) New Biomarker Data Mean For IgA Nephropathy?
      Nov 3Yahoo FinanceTVTX
      Travere: Q3 Earnings Snapshot
      Nov 3Yahoo FinanceTVTX
      What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
      Nov 3Yahoo FinanceTVTX
      Travere Q3 2026 slides: FILSPARI sales hit $200M milestone amid growth
      Nov 2Investing.comTVTX
      Travere Therapeutics Q3 2026 Earnings Call Transcript
      Nov 2BenzingaTVTX
      Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
      Nov 2Yahoo FinanceTVTX
      Travere Therapeutics Q3 Swings to Loss, Revenue Rises
      Nov 2Yahoo FinanceTVTX
      Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
      Nov 2Yahoo FinanceTVTX
      Travere Therapeutics falls on third quarter earnings miss
      Nov 2Investing.comTVTX
      Travere Therapeutics earnings missed by $0.57, revenue topped estimates
      Nov 2Investing.comTVTX
      Travere Therapeutics Reports Third Quarter 2026 Financial Results
      Nov 2Yahoo FinanceTVTX
      Travere faces earnings test as Filspari ramps commercialization
      Nov 2Investing.comTVTX
      Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Corcept Therapeutics (CORT) and Incyte (INCY)

      Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

      Oct 27The Globe and MailCORTTVTX
      Travere Therapeutics to Report Third Quarter 2026 Financial Results
      Oct 26Yahoo FinanceTVTX
      Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
      Oct 23Yahoo FinanceTVTX
      10 Health Care Stocks Whale Activity In Today’s Session
      Oct 23BenzingaABVXTVTX
      Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline
      Oct 22Yahoo FinanceTVTX
      Travere faces earnings test as Filspari expansion accelerates
      Oct 21Investing.comTVTX
      Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 12Yahoo FinanceTVTX
      Travere Therapeutics (TVTX) Is Down 6.7% After New FILSPARI Data And Patent Extension - What's Changed
      Oct 7Yahoo FinanceTVTX
      Travere to present FILSPARI data at ASN Kidney Week 2026
      Oct 2Investing.comTVTX
      Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

      SAN DIEGO, October 02, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI® (sparsentan) in patients with IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).

      Oct 2Yahoo FinanceTVTX
      Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
      Sep 30MorningstarTVTX
      Travere at Stifel forum: FILSPARI growth offsets leadership shift
      Sep 24Investing.comTVTXSF
      Guggenheim raises Travere Therapeutics stock price target on patent
      Sep 24Investing.comTVTX
      Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI

      Travere Therapeutics (TVTX) said Wednesday that it received a notice of allowance from the US Patent

      Sep 23Yahoo FinanceTVTX
      Travere receives patent allowance for FILSPARI use in FSGS
      Sep 23Investing.comTVTX
      Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

      SAN DIEGO, September 23, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," directed to certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain

      Sep 23Yahoo FinanceTVTX
      Travere Therapeutics (TVTX) Sets CEO Handover For December 2026

      Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric Dube will step down from his roles as CEO and President as part of the scheduled leadership change. Bradley L. Campbell has been appointed to succeed Dr. Dube, bringing experience from the rare disease biopharmaceutical sector. This CEO and President transition at Travere Therapeutics is an important development to set alongside the rest of the analysis. We have also...

      Sep 23Yahoo FinanceTVTX
      Travere Therapeutics appoints new CEO Bradley Campbell

      Tipranks Press Release.

      Sep 22The Globe and MailTVTX
      Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today

      Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on what investors are paying for its sales today. With the stock now reflecting years of optimism, the immediate question is how well the current valuation lines up with the revenue the business is actually generating. Over the last 3 years the share price has risen by roughly 7x, so anyone looking at Travere Therapeutics now is effectively asking how much of that move is...

      Sep 22Yahoo FinanceTVTX
      Travere Therapeutics stock falls amid CEO transition news
      Sep 21Investing.comTVTX
      Travere Therapeutics President and CEO Eric Dube Plans to Step Down
      Sep 21Yahoo FinanceTVTX
      Travere Therapeutics CEO Eric Dube to step down in December
      Sep 21Investing.comTVTX
      Travere Therapeutics Announces Planned Chief Executive Officer Transition

      SAN DIEGO, September 21, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer a

      Sep 21Yahoo FinanceTVTX
      Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing
      Sep 18Yahoo FinanceTVTX
      Travere Therapeutics Insider Sold Shares Worth $13,135,397, According to a Recent SEC Filing

      William E. Rote, Chief Research Officer, on September 15, 2026, sold 209,048 shares in Travere Thera

      Sep 18Yahoo FinanceTVTX
      Travere Therapeutics Insider Sold Shares Worth $2,337,695, According to a Recent SEC Filing
      Sep 18Yahoo FinanceTVTX
      Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing

      Eric M Dube, Director, Chief Executive Officer, on September 15, 2026, sold 400,000 shares in Traver

      Sep 18Yahoo FinanceTVTX

      This is the newest page. Registered accounts read further back.